CARLSBAD, California, July 2, 2026
Arima Genomics, Inc., a cancer diagnostics company advancing precision oncology through Hi-C sequencing technology, has announced an exclusive distribution partnership with Active Motif Incorporated, a global provider of epigenetics, genomics, and multiomics solutions. Under the agreement, Active Motif will become the exclusive distributor of Arima’s Hi-C sequencing kits and research services for non-clinical research applications, while Arima sharpens its strategic focus on expanding its clinical cancer diagnostics platform. The collaboration enables continued worldwide access to Arima’s advanced 3D genomics research technologies while allowing the company to concentrate resources on its rapidly growing Aventa clinical testing platform, which integrates DNA sequence and genome structure to identify cancer-driving genomic alterations that may be overlooked by conventional diagnostic methods. The partnership represents an important milestone in strengthening translational cancer research while accelerating innovation in precision oncology diagnostics and genomic medicine.
Strategic Partnership Expands Global Access to 3D Genomics Research
The new agreement grants Active Motif exclusive distribution rights for Arima’s complete portfolio of Hi-C research kits and sequencing services designed for non-formalin-fixed paraffin-embedded (non-FFPE) sample types, including cell lines, blood samples, and fresh-frozen tissues. These advanced research tools support a broad range of scientific applications, including epigenetics, gene regulation, chromatin biology, functional genomics, reference-quality genome assembly, haplotype phasing, and human disease research.
By leveraging Active Motif’s established global commercial network and extensive relationships within the life sciences research community, researchers worldwide will continue to access Arima’s innovative 3D genome mapping technologies. The collaboration combines Arima’s leadership in Hi-C sequencing with Active Motif’s expertise in delivering cutting-edge genomics and multiomics solutions, creating a stronger ecosystem for scientists investigating complex genomic architecture and disease mechanisms.
Arima Strengthens Focus on Precision Cancer Diagnostics
Advertisement
While transferring research distribution activities to Active Motif, Arima Genomics is strategically concentrating its efforts on expanding its clinical diagnostics business through the Aventa platform. Powered by proprietary Hi-C sequencing technology, Aventa combines DNA sequence analysis with three-dimensional genome structure to detect clinically significant genomic rearrangements, structural variants, and gene fusions that traditional sequencing approaches may miss or incompletely characterize. The platform currently supports Aventa FusionPlus for solid tumors and Aventa Lymphoma, both performed through Arima’s CLIA-certified laboratory.
By analyzing the structural organization of cancer genomes from routine FFPE tissue samples, the technology provides oncologists with more comprehensive molecular insights that can improve therapy selection and precision treatment decisions. Company leadership emphasized that integrating DNA sequence with genome architecture represents the future of precision oncology, enabling more accurate identification of cancer-driving alterations and expanding opportunities for personalized medicine.
Advancing Cancer Genomics Through Research and Clinical Innovation
The partnership reflects the growing convergence of advanced genomics, precision diagnostics, and translational research in modern oncology. As cancer diagnostics increasingly move beyond conventional DNA sequencing, technologies capable of analyzing three-dimensional genome organization are becoming valuable tools for understanding tumor biology, identifying structural rearrangements, and discovering novel therapeutic targets. Through this collaboration, Active Motif will continue supporting academic institutions, biotechnology companies, and pharmaceutical researchers with high-quality Hi-C sequencing technologies, while Arima Genomics accelerates development of innovative clinical diagnostics capable of improving patient care.
Backed by leadership in 3D genome science, the company aims to transform cancer testing by providing physicians with more comprehensive genomic information for informed treatment decisions. The strategic partnership therefore strengthens both scientific research and clinical innovation, supporting continued advances in precision oncology, molecular diagnostics, and genomic medicine while expanding global access to next-generation Hi-C sequencing technologies.
Source: Arima Genomics press release
